Skip to main content
. 2022 Dec 1;13:1023567. doi: 10.3389/fimmu.2022.1023567

Table 2.

Alternative isoform production associates with the incidence of infectious or inflammatory diseases.

Gene Pro Anti Association Both? Reference
MyD88 MyD88-L MyD88-S MyD88-L but not MyD88-S upregulated in PBMCs from ARDS patients Yes (140)
MyD88 MyD88-L MyD88-S MyD88-L but not MyD88-S upregulated in PBMCs from ILD patients undergoing an acute exacerbation Yes (140)
MyD88 MyD88-L MyD88-S HIV-1 exposed seronegative individuals: MyD88-L:MyD88-S ratio increased following TLR7/8 stimulation of PBMCs Yes (141)
MyD88 MyD88-L MyD88-S Major depressive disorder: MyD88-S downregulated compared to healthy controls in PBMCs/monocytes No (142144)
MyD88 MyD88-L MyD88-S MyD88-S upregulated in monocytes from septic patients No (145)
MyD88 MyD88-L MyD88-S No change in MyD88-S in monocytes from septic patients with severe melioidosis. No difference in MyD88-S in survivors vs non-survivors No (146)
MyD88 MyD88-L MyD88-S MyD88-S upregulated in COPD patient CD4+ T cells stimulated with αCD3/αC28 & IL12. No (147)
MyD88 MyD88-L MyD88-S No change in MyD88-L:MyD88-S ratio in human monocytes “tolerized” in vitro Yes (148)
MyD88 MyD88-L MyD88-S MyD88-L increased, MyD88-S unchanged in B cell lymphomas Yes (149)
IRAK1 IRAK1 IRAK1c IRAK1 splicing unchanged in PBMCs from ARDS patients. IRAK1c in PBMCs associated with decreased 28 day mortality in ARDS patients. Yes (140)
TLR4 TLR4 Unnamed Reduced ability to upregulate a possibly negatively acting isoform of TLR4 in LPS-stimulated monocytes from subjects with Cystic Fibrosis Yes (87)
TBK1 TBK1 TBK1s TBK1s but not TBK1 upregulated in PBMCs from HCV-infected patients Yes (66)

“Pro” is name of the canonical pro-inflammatory isoform. “Anti” is the name of the alternative splice form that encodes the negative regulator of signaling. Both refers to whether both isoforms were measured or only the anti-inflammatory form was measured in that study.